TB and Women, on International Women’s Day 2023
Photo: Mariia, a resident of Lviv, Ukraine who was successfully treated with TB Alliance’s six-month regimen for drug-resistant TB in […]
News
TB Alliance Announces David Norton as Board Chair
NEW YORK (February 23, 2023)—The TB Alliance Board of Directors has elected David Norton as Chairperson of the Board. In
Fireside Chat with Bruce Carter
We spoke with Bruce Carter, outgoing Chair of the TB Alliance Board of Directors, about his seventeen years serving as
SimpliciTB Trial Results Presented at CROI 2023
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference.
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
SEONGNAM-SI, South Korea and NEW YORK, US. Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South
Innovation Deficit: Funds for Neglected Diseases like TB are Falling Short
NEW YORK (January 31, 2023)—The 2022 G-FINDER Report, released today, reveals that for the year 2021, global funding for the
8 Things to Know about Drug-Resistant Tuberculosis
By: Sandeep Juneja, Senior Vice President, Market Access Drug-resistant tuberculosis (DR-TB) forms when long, complex, outdated drug regimens are improperly
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
19 December 2022: Viatris, a global healthcare company, MedAccess, and TB Alliance have announced a new agreement to reduce the
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will